Cardinal Health, Inc. (ETR:CLH)
Germany · Delayed Price · Currency is EUR | Market Cap | 48.72B +43.7% |
| Revenue (ttm) | 217.46B +12.8% |
| Net Income | 1.35B -0.1% |
| EPS | 5.67 +2.5% |
| Shares Out | n/a |
| PE Ratio | 36.12 |
| Forward PE | 20.14 |
| Dividend | 1.98 (0.96%) |
| Ex-Dividend Date | Jul 1, 2026 |
| Volume | n/a |
| Open | 209.90 |
| Previous Close | 206.70 |
| Day's Range | 209.90 - 209.90 |
| 52-Week Range | 178.70 - 210.30 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products.... [Read more]
Financial Performance
In fiscal year 2025, Cardinal Health's revenue was $222.58 billion, a decrease of -1.87% compared to the previous year's $226.83 billion. Earnings were $1.56 billion, an increase of 83.22%.
Financial numbers in USD Financial StatementsNews
Cardinal Health price target raised to $275 from $255 at TD Cowen
TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $275 from $255 and keeps a Buy rating on the shares. The firm updated its model ahead of…
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of tra...
Cardinal Health price target raised to $260 from $240 at BofA
BofA raised the firm’s price target on Cardinal Health (CAH) to $260 from $240 and keeps a Buy rating on the shares, citing relative upside to consensus estimates and strong…
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
Cardinal Health Transcript: Bank of America Global Healthcare Conference 2026
Strong Q3 profit growth and raised guidance reflect robust demand and operational execution across all segments. Strategic M&A in GI and urology, investments in innovation, and disciplined capital allocation support long-term growth and resilience.
Cardinal Health Board of Directors Approves Quarterly Dividend
DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Compa...
Cardinal Health price target lowered to $215 from $243 at JPMorgan
JPMorgan analyst Lisa Gill lowered the firm’s price target on Cardinal Health (CAH) to $215 from $243 and keeps a Neutral rating on the shares.
Cardinal Health price target lowered to $248 from $257 at Baird
Baird lowered the firm’s price target on Cardinal Health (CAH) to $248 from $257 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results…
Cardinal Health price target raised to $255 from $251 at TD Cowen
TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $255 from $251 and keeps a Buy rating on the shares. The firm updated its model following quarterly…
Cardinal Health price target lowered to $245 from $249 at Citi
Citi analyst Daniel Grosslight lowered the firm’s price target on Cardinal Health (CAH) to $245 from $249 and keeps a Buy rating on the shares.
Cardinal Health price target lowered to $240 from $260 at BofA
BofA lowered the firm’s price target on Cardinal Health (CAH) to $240 from $260 to reflect lower peer multiples, while keeping a Buy rating on the shares. The firm notes…
Cardinal Health raises FY26 EPS view to $10.70-$10.80 from $10.15-$10.35
Consensus $10.31. Raises FY26 adjusted free cash flow view to $3.3B-$3.7B from $3B-$3.5B. Lowers FY26 tax rate view to 19% from 21%-23%.
Cardinal Health Earnings Call Transcript: Q3 2026
Q3 saw double-digit revenue and profit growth, led by specialty and pharma, with robust results in other growth businesses. Guidance for EPS and free cash flow was raised, reflecting operational strength, tax benefits, and successful M&A integration.
Cardinal Health Earnings release: Q3 2026
Cardinal Health released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.
Cardinal Health Slides: Q3 2026
Cardinal Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 30, 2026.
Cardinal Health Quarterly report: Q3 2026
Cardinal Health has published its Q3 2026 quarterly earnings report on April 30, 2026.
Cardinal Health Rises. A Guidance Hike Powers the Stock Past These Weak Points.
Cardinal Health raises its fiscal-year adjusted earnings guidance for the second time this year, helping investors look past mixed quarterly performance.
Cardinal Health Lifts Outlook Again as Revenue Rises
Cardinal Health once again raised its full-year outlook after logging higher-than-expected adjusted earnings in the third quarter.
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
Cardinal Health reports Q3 EPS $3.17, consensus $2.79
Reports Q3 revenue $60.94B, consensus $62.24B. “An excellent third quarter extends our FY26 momentum, due to the durability and resilience of our business,” said Jason Hollar, CEO of Cardinal Health…
Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
Revenue increased 11% to $60.9 billion GAAP 1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69 Non-GAAP operating earnings increased 18% to $956 million; non-G...
Cardinal Health initiated with an Outperform at William Blair
William Blair initiated coverage of Cardinal Health (CAH) with an Outperform rating. The firm says the company’s pharmaceutical distribution platform creates a “durable competitive moat” and supports ...
Cramer says look to these 4 stocks to go with your high-flying tech names
CNBC's Jim Cramer urged investors to look at parts of the market that have already been beaten down. He highlighted four stocks in the health-care sector as alternatives to high-flying technology and ...
Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, O...